Kura Oncology is a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its lead product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of human farnesyl transferase. Kura in-licensed tipifarnib from Janssen Pharmaceuticals in December 2014 and has worldwide rights in all indications except virology. Tipifarnib has been studied in over 5,000 oncology patients and is currently being studied in four Phase II clinical trials in the following indications: HRAS mutant SCCHN, PTCL, MDS and CMML